In addition, investigations about the SWI/SNF complexes and polycomb-repressive complexes in cancer have indicated that cancers that harbor SWI/SNF subunits mutations or deletions are sensitive to the inhibition of EZH2. This evidence concerns the gene SMARCA1 and cancer.